Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Preferred Stock Liabilities: 2015-2016

  • Intellia Therapeutics' Preferred Stock Liabilities was N/A to $88.6 million in Q1 2016 from the same period last year, while for Mar 2016 it was $88.6 million, marking a year-over-year change of. This contributed to the annual value of $88.6 million for FY2015, which is N/A change from last year.
  • Per Intellia Therapeutics' latest filing, its Preferred Stock Liabilities stood at $88.6 million for Q1 2016, which was up 0.07% from $88.6 million recorded in Q4 2015.
  • Over the past 5 years, Intellia Therapeutics' Preferred Stock Liabilities peaked at $88.6 million during Q1 2016, and registered a low of $88.6 million during Q4 2015.
  • Moreover, its 2-year median value for Preferred Stock Liabilities was $88.6 million (2015), whereas its average is $88.6 million.